Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toward Cost-efficient Adaptive Clinical Trials in Knee Osteoarthritis with Reinforcement Learning.

IEEE journal of biomedical and health informatics·2026

Same author

Diagnostic stewardship in emergency departments using the UNTIE framework: a stepped-wedge cluster randomised study protocol.

BMJ open·2026

Same author

Metformin Redirects Autophagy from Bulk Turnover to Mitochondrial Clearance.

bioRxiv : the preprint server for biology·2026

Same author

Age-related macular degeneration severity and risk of Alzheimer's disease in older adults in a prospective, community-based cohort study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

Clinical Characteristics and Outcomes of Hospitalized Patients With COVID-19 and Type 2 Diabetes in Vietnam: A Retrospective Study.

Cureus·2026

Same author

Luminal surface proteome of the brain vasculature uncovers blood-brain barrier regulators.

Science (New York, N.Y.)·2026

Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026

Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026

Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026

Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026

Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026

Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 7, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Blueprint for antibody biologics developability.

Carl Mieczkowski¹, Xuejin Zhang¹, Dana Lee¹

¹Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA.

|March 7, 2023

Summary

This summary is machine-generated.

This review details preclinical antibody developability, crucial for selecting successful biologic drug candidates. It covers key activities and molecular properties influencing clinical progression and manufacturability.

Keywords:

Antibody biologics colloidal conformational developability formulation manufacturability specificity stability

More Related Videos

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Related Experiment Videos

Last Updated: Aug 7, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Area of Science:

Biopharmaceutical development
Medicinal chemistry
Protein engineering

Background:

Large-molecule antibody biologics offer superior specificity and engineered properties, revolutionizing medicine.
Preclinical developability assessment is critical for successful biologic drug candidate selection and clinical progression.

Purpose of the Study:

To define and scope preclinical antibody developability.
To outline key activities and molecular properties impacting antibody developability outcomes.
To explore emerging workflows and strategies for successful biologic drug development.

Main Methods:

Review of preclinical antibody developability activities from hit to lead optimization.
Analysis of computational, molecular engineering, production, and characterization approaches.
Examination of stability, degradation, process, and formulation assessments.

Main Results:

Developability activities influence lead selection, manufacturability, and clinical success.
Four major molecular properties (conformational, chemical, colloidal, other interactions) affect developability.
Risk assessment and mitigation strategies enhance the likelihood of clinical progression.

Conclusions:

A comprehensive understanding of antibody developability is essential for advancing biologic therapeutics.
Integrating developability assessments early optimizes candidate selection and manufacturing.
Strategic risk management is key to successful translation of antibody candidates into the clinic.